MAGED4 expression in glioma and upregulation in glioma cell lines with 5-Aza-2'-deoxycytidine treatment

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 8, 2014, Pages 3495-3501

  Zhang, Qing Mei ^a   Shen, Ning ^b   Xie, Sha ^a   Bi, Shui Qing ^b   Luo, Bin ^a   Lin, Yong Da ^a   Fu, Jun ^a   Zhou, Su Fang ^a,b   Luo, Guo Rong ^a,b   Xie, Xiao Xun ^a,b   Xiao, Shao Wen ^b  

^a Department of Histology and Embryology School of Pre clinical Medicine   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Expression; Glioma; MAGED4; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; MAGE-E1 ANTIGEN, HUMAN; MESSENGER RNA; TUMOR ANTIGEN; TUMOR MARKER;

ANALOGS AND DERIVATIVES; CPG ISLAND; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; HUMAN; METABOLISM; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION;

ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84902003286     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.8.3495     Document Type: Article

References (34)

1. Ahmed Ali HA, Di J, Mei W, et al (2014). Antitumor activity of lentivirus-mediated interleukin-12 gene modified dendritic cells in human lung cancer in vitro. Asian Pac J Cancer Prev, 15, 611-6.
2. Becher B, Prat A, Antel JP (2000). Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia, 29, 293-304.
3. Cen YH, Guo WW, Luo B, et al (2012). Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biol Int, 36, 917-22.
4. Chi DD, Merchant RE, Rand R, et al (1997). Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol, 150, 2143-52.
5. Chong CE, Lim KP, Gan CP, et al (2012). Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett, 321, 18-26.
6. Coral S, Sigalotti L, Altomonte M, et al (2002). 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res, 8, 2690-5.
7. Dhodapkar MV, Osman K, Teruya-Feldstein J, et al (2003). Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun, 3, 9.
8. Dos Santos NR, Torensma R, De Vries TJ, et al (2000). Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res, 60, 1654-62.
9. Duffour MT, Chaux P, Lurquin C, et al (1999). A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol, 29, 3329-37.
10. Germano S, Kennedy S, Rani S, et al (2011). MAGED4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer, 130, 1991-2002.
11. Inoue H, Mori M, Honda M, et al (1995). The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology, 109, 1522-5.
12. Ito S, Kawano Y, Katakura H, et al (2006). Expression of MAGED4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. Lung Cancer, 51, 79-88.
13. Kawano Y, Sasaki M, Nakahira K, et al (2001). Structural characterization and chromosomal localization of the MAGE-E1 gene. Gene, 277, 129-37.
14. Kramer BF, Schoor O, Kruger T, et al (2005). MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther, 4, 943-8.
15. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.
16. Luo B, Yun X, Fan R, et al (2013). Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol, 6, 2835-45.
17. Meek DW, Marcar L (2012). MAGE-A antigens as targets in tumour therapy. Cancer Lett, 324, 126-32.
18. Morse MA, Garst J, Osada T, et al (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med, 3, 9.
19. Ohgaki H, Kleihues P (2005). Epidemiology and etiology of gliomas. Acta Neuropathol, 109, 93-108.
20. Prins RM, Odesa SK, Liau LM (2003). Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res, 63, 8487-91.
21. Rosenberg SA, Yang JC, Restifo NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med, 10, 909-15.
22. Sampson JH, Archer GE, Ashley DM, et al (1996). Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA, 93, 10399-404.
23. Sasaki M, Nakahira K, Kawano Y, et al (2001). MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res, 61, 4809-14.
24. Serrano A, Garcia A, Abril E, Garrido F, Ruiz-Cabello F (1996). Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int J Cancer, 68, 464-70.
25. Sigalotti L, Coral S, Nardi G, et al (2002). Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother, 25, 16-26.
26. Sigalotti L, Fratta E, Coral S, et al (2004). Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res, 64, 9167-71.
27. Thaker PH, Deavers M, Celestino J, et al (2004). EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res, 10, 5145-50.
28. Weber J, Salgaller M, Samid D, et al (1994). Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res, 54, 1766-71.
29. Wischnewski F, Pantel K, Schwarzenbach H (2006). Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res, 4, 339-49.
30. Wu TF, Zhang W, Su ZP, et al (2012). UHRF2 mRNA expression is low in malignant glioma but silencing inhibits the growth of U251 glioma cells in vitro. Asian Pac J Cancer Prev, 13, 5137-42.
31. Yang L, Ng KY, Lillehei KO (2003). Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control, 10, 138-47.
32. Zeybek U, Yaylim I, Ozkan NE, et al (2013). Cyclin D1 Gene G870A Variants and Primary Brain Tumors. Asian Pac J Cancer Prev, 14, 4101-6.
33. Zhang J, Yu J, Gu J, et al (2004). A novel protein-DNA interaction involved with the CpG dinucleotide at -30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene. Cell Res, 14, 283-94.
34. Zhang SC, Huang P, Zhao YX, et al (2013). Soluble expression of recombinant human Smp30 for detecting serum Smp30 antibody levels in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 14, 2383-6.